PDUFA dates July 2024: FDA calendar and catalysts.
2 PDUFA dates fell in July 2024: TLX007 (Jul 2024), ZUNVEYL (July 27). The FDA calendar also recorded 43 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in July 2024
| PDUFA date | Company | Ticker | Drug | Indication | Source |
|---|---|---|---|---|---|
| Jul 2024 | Telix Pharmaceuticals Ltd | TLX | TLX007 | SEC Form 10-K, filed 2025-02-24 | |
| July 27, 2024 | Alpha Cognition Inc. | ACOG | ZUNVEYL (benzgalantamine) | sec_s1, filed 2024-12-31 |
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
July 2024: other FDA decisions and filings
July 2024: dated readouts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Jul 2024Month disclosed | biosimilar | ALVO | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| Jul 2024Month disclosed | — | BNTX | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| Jul 2024Month disclosed | nebokitug (CM-101) | CMMB | Topline readout | — | Positive | sec_424b |
| Jul 2024Month disclosed | — | HUMA | Topline readout | — | Met primary endpoint | SEC Form 10-Q |
| Jul 2024Month disclosed | ZYNYZ (retifanlimab) | INCY | Topline readout | — | Positive | SEC Form 10-Q |
| Jul 2024Month disclosed | Mytesi® (crofelemer) | JAGX | Topline readout | — | Missed primary endpoint | sec_424b |
| Jul 2024Month disclosed | obicetrapib | NAMS | Topline readout | — | Met primary endpoint | SEC Form 10-K |
| July 1, 2024 | GV101 | OVID | Topline readout | cerebral cavernous malformations | Positive | SEC Form 10-Q |
| July 17, 2024 | ATH434 | ATHE | Interim readout | advanced MSA | Positive | SEC 8-K Exhibit 99.1 |
| July 25, 2024 | chemomab | CMMB | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| July 28, 2024 | ATH434 | ATHE | Topline readout | multiple system atrophy | Positive | SEC 8-K Exhibit 99.1 |
| July 30, 2024 | — | IMNN | Topline readout | — | Positive | SEC Form 10-Q |
| July 30, 2024 | — | IMNN | Topline readout | — | Positive | SEC Form 10-Q |
| July 30, 2024 | INM-901 | MTRI | Interim readout | — | Positive | SEC Form 10-Q |
July 2024: trial starts and primary completions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Jul 2024Month disclosed | INT230 | INTS | Trial start | — | Completed | sec_424b |
| Jul 2024Month disclosed | envudeucitinib (ESK-001) | ALMS | Trial start | — | Completed | SEC Form 10-Q |
| Jul 2024Month disclosed | mivelsiran | ALNY | Trial start | CAA and in July 2026, we | Completed | SEC Form 10-Q |
| Jul 2024Month disclosed | CM5480 | CALC | Trial start | — | Completed | SEC Form 10-Q |
| Jul 2024Month disclosed | abiprubart (KPL-404) | KNSA | Trial start | — | Completed | SEC Form 10-K |
| Jul 2024Month disclosed | dinger (SGR-3515) | SDGR | Trial start | advanced solid tumors | Completed | SEC Form 10-Q |
3 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps July 2024. They are on each drug page and in the calendar API.
Questions
What PDUFA dates are in July 2024?
2 PDUFA dates fell in July 2024: TLX007 (Jul 2024), ZUNVEYL (July 27). The FDA calendar also recorded 43 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.